Financial results for quarter and year ended on March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prevest Denpro Limited reported its audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone revenue from operations rose about 8.5% year-on-year to Rs. 64.32 crore, while total income grew roughly 13% to Rs. 67.18 crore. Net profit increased around 13% to Rs. 18.20 crore (from Rs. 16.12 crore), lifting basic EPS to Rs. 15.16 from Rs. 13.44. The company continues to carry zero long-term debt, with cash and equivalents strengthening to Rs. 60.46 crore, and paid an increased dividend of Rs. 1.20 crore during the year. Statutory auditor Mittal & Associates issued an unmodified (clean) opinion on both standalone and consolidated results; the consolidated numbers include two wholly-owned subsidiaries, Denvisio Biomed Limited and Axiodent INC.
Steady profit growth, a debt-free balance sheet with a rising cash pile, expanding margins and a higher dividend payout are positive signals for shareholders. However, revenue growth is in single digits, so the stock is likely to see a stable rather than a sharp move.